OCTOBER 26, 2020
Biophytis Enrolls First Patient in Brazil in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release
Biophytis Enrolls First Patient in Brazil in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release
Biophitys will participate in the following events: Mid-Cap Event :October 19 & 20th Galien Week of Innovation: Oct 26-30
First US Patient Enrolled in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release
Biophytis Trading will resume on September 30, 2020 at 3.00pm CEST. Read the Press Release
Biophytis announces a € 10 million capital increase through private placement. Read the Press Release
Biophytis shares and BSA trading is suspended pending a new press release. Read the Press Release
Biophytis Reports H1 2020 Financial Results and Provides Business Update. Read the Press Release
Biophytis announces the issuance of a €3 million tranche of ORNANE. Read the Press Release
Biophytis recently attended the Digital ChinaBio conference taking place August 25-27, and will also attend the following conferences: The HC Wainwright 22nd Annual Global Investment Conference – September 14-16, 2020 (Virtual Conference) The HTID (Health Tech Innovation Days): October 5th & 6th, Paris Bio Europe Fall : October 26-29th (Virtual Conference)
Biophytis Enrolls First Patient in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release